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Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive
decline of cognitive function. Astrogliosis plays a critical role in AD by instigating
neuroinflammation, which leads ultimately to cognition decline. We previously showed
that the intermediate-conductance Ca2+-activated potassium channel (KCa3.1) is
involved in astrogliosis-induced by TGF-β in vitro. In the present study, we investigated
the contribution of KCa3.1 channels to astrogliosis-mediated neuroinflammation, using
TgAPP/PS1 mice as a model for AD. We found that KCa3.1 expression was increased
in reactive astrocytes as well as in neurons in the brains of both TgAPP/PS1 mice and
AD patients. Pharmacological blockade of KCa3.1 significantly reduced astrogliosis,
microglial activation, neuronal loss, and memory deficits. KCa3.1 blockade inhibited
astrocyte activation and reduced brain levels of IL-1β, TNF-α, iNOS, and COX-
2. Furthermore, we used primary co-cultures of cortical neurons and astrocytes to
demonstrate an important role for KCa3.1 in the process of astrogliosis-induced
neuroinflammatory responses during amyloid-β (Aβ)-induced neuronal loss. KCa3.1
was found to be involved in the Aβ-induced activated biochemical profile of reactive
astrocytes, which included activation of JNK MAPK and production of reactive
oxygen species. Pharmacological blockade of KCa3.1 attenuated Aβ-induced reactive
astrocytes and indirect, astrogliosis-mediated damage to neurons. Our data clearly
indicate a role for astrogliosis in AD pathogenesis and suggest that KCa3.1 inhibition
might represent a good therapeutic target for the treatment of AD.
Highlights:
(1) Blockade of KCa3.1 in APP/PS1 transgenic mice attenuated astrogliosis and
neuron loss, and an attenuation of memory deficits. (2) Blockade of KCa3.1 attenuated
Aβ-induced indirect, astrogliosis-mediated damage to neurons in vitro via activation of
JNK and ROS.
Keywords: astrogliosis, Alzheimer’s disease, GFAP, inflammation, neurons
Abbreviations: CM-H2DCFDA, 5-(and–6)-chloromethyl–2′,7′-dichlorodihydrofluorescein diacetate; GFAP, glial fibrillary
acidic protein; KCa3.1, intermediate-conductance calcium-activated potassium channel; TGF-β, transforming growth factor-
β; TRAM-34, 1-[(2-chlorophenyl)(diphenyl)methyl]-1H-pyrazole.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by progressive decline of cognitive function. The
proposed mechanisms of cognitive impairment include synaptic
dysfunction triggered by β-amyloid (Aβ), neuronal death,
oxidative stress, tau pathology, and glutamate excitotoxicity. It is
widely acknowledged that reactive gliosis plays a significant role
in the progression of AD. Accumulation of reactive astrocytes
and activation of microglia in affected brain regions are apparent
in both AD patients and the majority of transgenic rodent
models of AD. Garwood et al. (2011) reported that reactive
astrogliosis is involved in regulating Aβ-induced neurotoxicity
and tau phosphorylation. Reactive astrocytes release a variety
of cytokines and pro-inflammatory mediators, which activate
intracellular signaling pathways including extracellular signaling-
related kinase (ERK), c-Jun N-terminal kinase (JNK), protein
kinase C and PI3 kinase (Matos et al., 2008).
It has been reported that brief (5–15 min) application of Aβ
to mixed disassociated hippocampal cultures evoked Ca2+ influx
and up-regulated reactive oxygen species (ROS) in astrocytes, but
not in neurons, whereas longer (24 h) exposure led to cell death,
especially in neurons (Abramov et al., 2003). Although these data
indicate that the primary target of Aβmight be astrocytes and that
Aβ-induced oxidative stress and calcium overload in astrocytes
may lead to neuronal death, the mechanism of these effects is not
well understood.
In immune cells, airway smooth muscle cells and fibroblasts,
the intermediate-conductance Ca2+-activated potassium channel
KCa3.1 regulates membrane potential through K+ eﬄux, thus
facilitating Ca2+ entry (Toyama et al., 2008; Di et al., 2010;
Yu et al., 2013; Yi et al., 2016a). In the central nervous
system (CNS), KCa3.1 plays a role in neuroprotection following
traumatic brain injury, stroke and spinal cord injury (Bouhy et al.,
2011). Up-regulation of KCa3.1 has been detected in reactive
astrocytes in a mouse model of spinal cord injury. We have
previously reported that blockade of KCa3.1, or gene deletion,
attenuated TGF-β-induced astrogliosis by regulating intracellular
Ca2+ in primary astrocytes (Yu et al., 2014). Yi et al. (2016a)
reported that KCa3.1 is involved in scratch-induced migration
of reactive astrocytes mediated by the JNK/c-Jun pathway. More
recently, we demonstrated that blockade of KCa3.1 in senescence-
accelerated mouse prone 8 (SAMP8) mice resulted in a decrease
in astrogliosis and, moreover, an attenuation of memory deficits
(Yi et al., 2016b). Evidence was found for astrogliosis in AD
patients with mild cognitive impairment in a positron emission
tomography study (Carter et al., 2012). Most recently, Schöll
et al. (2015) reported that measure of astrogliosis in autosomal
dominant AD could be observed decades before symptom
onset using multi-tracer positron emission tomography, possibly
coinciding with early fibrillar Aβ plaque deposition. Although
reactive astrogliosis has long been recognized as a pathological
feature of AD, the role of astrogliosis in the process of cognitive
decline in AD is still poorly understood.
In the present study, we showed that blockade of KCa3.1
attenuated Aβ-induced changes in the biochemical profile
of reactive astrocytes, including activation of JNK MAP
kinase (MAPK) and production of ROS. An experimental
KCa3.1 blocker, TRAM-34, attenuated Aβ-induced, indirect,
astrogliosis-mediated damage to neurons in vitro, decreased
astrogliosis and neuronal loss, and attenuated memory deficits in
APPSwe/PS1A246E transgenic (TgAPP/PS1) mice in vivo.
MATERIALS AND METHODS
Brain Autopsy Material
Human brain sections were collected from six AD cases
and six control cases (Netherlands Institute for Neuroscience,
Amsterdam, Netherlands). Written informed consent for a brain
autopsy to be used for research purposes after death had been
obtained by the Netherlands Brain Bank.
Animals
Nine-month male transgenic mice (the Jackson Lab, no. 003378,
TgAPP/PS1) were purchased from the Jackson lab. Mice were
divided into the following three groups: littermate wild type
(WT) mice (n= 20), transgenic (Tg) mice with vehicle treatment
(n= 20) or TRAM-34 (120 mg/kg, intraperitoneal, Apptec, Wuxi,
China) treatment (Tg+TRAM-34, n= 20). After 4 weeks of drug
treatment, the mice were submitted to behavioral testing, and
then the mice were euthanized and brain tissues were collected
for Western blotting or histology analyses. The protocol of animal
experiments was approved by the Animal Experimentation
Ethics Committee of Shanghai Jiao Tong University School of
Medicine.
Morris Water Maze Test
A modified Morris water maze test was carried out as previously
described (Morris, 1984). The test requires the animals to
find a visible or hidden platform in a large pool of opaque
water and involves 5 days of training sessions (1 day with
the platform visible and 4 days with the platform hidden),
followed by a spatial probe trial, with no platform present,
on day 6. During the hidden platform training, the mice
were able to swim freely for 60 s to find a platform 1 cm
below the water surface. During the spatial probe trial, the
directness of the route taken to the area where the platform was
previously located, together with the percentage of total time
spent in this quadrant of the pool, was recorded using a video
tracking system (Jiliang Software Technology Co., Ltd., Shanghai,
China).
Open Field Test
The open field test was carried out as described previously (Wu
et al., 2016). Briefly, the mouse was gently placed in the center of
an open field chamber (40 cm× 40 cm× 40 cm) and was allowed
to move freely for 5 min. The movement parameters of the mouse
were monitored and analyzed via a video camera connected to a
tracking system (Jiliang Software Technology Co., Ltd., Shanghai,
China). After each test, the floor of the open field was cleaned
with solution of 70% ethanol to hide animal clues. The ratios of
distance and time in the center were measured.
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Immunostaining and Data Analysis
The mice were anesthetized with chloral hydrate and perfused
with 4% paraformaldehyde. The brain tissues were collected
and cryoprotected with 30% sucrose in 0.1 M phosphate
buffered saline (PBS). Brain sections (12 µm thick) were blocked
with 3% bovine serum albumin in 0.1 M PBS for 1 h at
room temperature and were then incubated with the following
primary antibodies: mouse anti-KCa3.1 (1:200, Santa Cruz),
rabbit anti-GFAP (1:1000; DAKO, Glostrup, Denmark), rabbit
anti-NeuN (1:100, Millipore), rabbit anti-Iba1 (1:500, Wako) at
4◦C overnight. Brain sections were labeled with either Alexa
Fluor 488- or 568-conjugated anti-mouse or rabbit IgG (1:1000,
Invitrogen). A TCS SP8 confocal laser scanning microscope
(Leica, Germany), equipped with an argon-ion laser source, was
used to capture images using excitation wavelengths of 405, 488,
and 568 nm for DAPI, Alexa 488 and Alexa 568, respectively.
Using the same reference position for each brain slice, between
three and five random 0.01 mm2 microscopic fields were selected
for quantification. Quantification was carried out in six slices of
each brain (120 µm intervals), using immunoreactivity for GFAP,
Iba1, and NeuN expression. The numbers of GFAP+, Iba1+, and
NeuN+ positive cells were counted in six slices per mouse in a
blinded manner, using Leica LAS AF Lite software to measure the
areas.
Senile Plaque Staining
For senile plaques staining, coronal sections (12 µm) were
cut using a Leica cryostat (Leica CM1850). Primary 6E10
antibody (SIG-39300, Covance, Princeton, NJ, USA) was used
on the sections overnight at 4◦C. Sections were incubated with
biotinylated secondary antibody (AK-6602, Vector) for 45 min.
Sections were developed using the ABC elite kit (AK-6600,
Vector). Image-Pro plus software (Media cybernetics, USA) was
used to measure and recorded as the average plaque areas per
field. Six slices per mouse were used to count the plaque number
in a blinded manner.
Enzyme-Linked Immunosorbent Assay
ELISA was performed using the kit for TNF-α and IL-1β
(Rapidbio Labs, Langka Trade Co. Ltd., Shanghai, China).
The procedures were conducted according to manufacturer’s
protocols.
Preparation of Oligomeric Aβ1−42
Peptides
Our preparation of oligomeric amyloid β (Aβ1-42) follows
the procedure described previously (Wang et al., 2012). As
described previously, monomeric peptide Aβ1-42 was initially
dissolved in 1,1,1,3,3,3-hexafluoro 2-propanol (HFIP, Sigma, St.
Louis, MO, USA) at 1 mg/ml. Dried peptides were resolved in
dimethyl sulfoxide (DMSO), diluted to 100 µM with ddH2O, and
incubated at 4◦C for 24 h.
Primary Cultures
Primary cortical astrocyte cultures derived from neonatal (P0–
P2) C57BL/6J mice were prepared from mixed glial cultures
(10–14 days in vitro) as described previously (Wang et al., 2008).
Astrocyte-conditioned medium (ACM) for treating neurons
was obtained using the following procedure. Firstly, astrocytes
were cultured in Dulbecco’s Modified Eagle’s medium (DMEM)
contained 10% fetal bovine serum. The culture medium (CM)
was changed to neurobasal medium with B27 supplement
(Invitrogen) after confluent astrocytes were serum-free for
24 h. The NB/B27-based astrocytes were then treated with
Aβ1−42 oligomer (5 µM) for different lengths of time. The
CM from the NB/B27-based cells was collected and used
immediately.
Neuronal cultures were established by adding cytosine
arabinoside (2 µM) to the mixed glial cultures to inhibit
proliferation of glial cells. The neurons were cultured for at least
14 days before treatment with astrocytes CM.
Primary mixed cortical cells were isolated from neonatal
(P0–P2) C57BL/6J mice and cultured as described previously
(Rodriguez-Gonzalez et al., 2016). Briefly, astrocytes were
collected and seeded in multiwell plates in DMEM. Four days
after plating, neurons were obtained from brain cortices of P0
C57BL/6J mice and seeded on top of the astrocyte layer.
A Cell Counting Kit-8 (CCK-8, Dojindo Laboratories,
Kumamoto, Japan) was used to measure cell viability (Yu et al.,
2013).
Neurite Outgrowth Assay
Aβ1−42 oligomers were added to the primary cultured neurons
with or without TRAM-34 and then stained with primary
antibody microtubule associated protein 2 (MAP2) plus
Alexa Fluor 555-conjugated secondary antibody and DAPI.
Cellomics KineticScan reader was used to scan the MAP2
positive cells. Extended Neurite Outgrowth software (Thermo
Scientific, Philadelphia, PA, USA) was used to analyze the
data.
Western Blot Analysis
Protein extracts were separated by 10 % (w/v) sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and were transferred
to polyvinylidene difluoride membrane. The membrane was
incubated with following primary antibodies for anti-total
p38/JNK/ERK MAPK, anti-phospho-p38/JNK/ERK MAPK
antibodies (1:1000, Cell Signaling Technology, Danvers, MA,
USA), anti-Synaptophysin antibody (1:1000, Abcam), anti-
PSD95 antibody (1:1000, Abcam), anti-NeuN antibody (1:1000,
Millipore), anti-MAP2 antibody (1:1000, Abcam), anti-GFAP
antibody (1:5000, Dako, Glostrup, Denmark), anti-KCa3.1
antibody (1:400, Abcam), and anti-β-actin antibody (1:3000,
Sigma). Secondary antibodies were horseradish peroxidase-
conjugated antibody (1:3000; Amersham Biosciences) for 1 h at
room temperature.
Reactive Oxygen Species Measurement
Aβ1−42 oligomers were added to the primary cultured astrocytes
with or without TRAM-34. Astrocytes were loaded with 30µM 5-
(and-6)-chloromethyl–2′,7′-dichlorodihydrofluorescein diacet-
ate (CM-H2DCFDA, Invitrogen, Waltham, CA, USA) to measure
ROS generation as previously described (Alberdi et al., 2013).
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FIGURE 1 | Up-regulation of KCa3.1 channels in astrocytes and neurons in TgAPP/PS1 mouse brains. Immunofluorescence double staining of KCa3.1
(green) with GFAP, NeuN, or Iba1 (red) in brain sections of 9 month old wild type (WT) and TgAPP/PS1 mice. Co-staining of (A) KCa3.1 and GFAP, (B) KCa3.1 and
NeuN, and (C) KCa3.1 and Iba1 in WT and TgAPP/PS1 mice. Arrows indicate co-labeling of (A) KCa3.1 and GFAP, (B) KCa3.1 and NeuN, and (C) KCa3.1 and Iba1.
Views are enlarged in the adjacent panels. Nuclei are stained blue with DAPI. Scale bars: (A) 25 µm, (B) 50 µm, and (C) 25 µm.
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FIGURE 2 | Up-regulation of KCa3.1 channels in astrocytes and neurons in brains of Alzheimer’s disease (AD) patients. Immunofluorescence double
staining of KCa3.1 (green) with GFAP, NeuN, or Iba1 (red) in brain slices of healthy individuals and AD patients. Co-staining of (A) KCa3.1 and GFAP, (B) KCa3.1 and
NeuN, and (C) KCa3.1 and Iba1 in healthy individuals and AD patients. Arrows indicate double staining of (A) KCa3.1 and GFAP, (B) KCa3.1 and NeuN, and
(C) KCa3.1 and Iba1. Nuclei are stained blue with DAPI. Scale bar: 25 µm.
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FIGURE 3 | Blockade of KCa3.1 rescued memory deficits and spontaneous motor activity in TgAPP/PS1 mice. The Morris water maze test (A–C) and open
field test (D,E) were performed on 9 months old mice as described in the section “Materials and Methods.” TgAPP/PS1 mice were treated with vehicle or TRAM-34
(120 mg/kg, intraperitoneally) daily for 4 weeks. (A) Average latency to hidden platform, (B) Percentage of time spent by each group swimming in target quadrant
during probe trial (no platform), (C) Percentage of total swim distance by each group in target quadrant during probe trial (no platform), (D,E) Exploratory locomotion
of the open field test, (D) Ratio of distance in exploratory locomotion of the open field test, and (E) Ratio of time in center in exploratory locomotion of the open field
test. TgAPP/PS1 group showed decreased locomotion compared with TgAPP/PS1 + TRAM-34 (120 mg/kg, intraperitoneally) group. Data represent mean ± SEM
(n = 20 per group). ##p < 0.01 versus WT mice. ∗p < 0.05 versus vehicle-treated TgAPP/PS1 mice. Tg, TgAPP/PS1.
Statistical Analysis
Statistical significance was analyzed using the Student’s t-
test, one-way ANOVA followed by Dunnett’s post hoc tests
or two way ANOVA followed by Bonferroni post hoc test,
depending on the case, using Prism software (GraphPad
Software, Inc., La Jolla, CA, USA). Results are presented as
Mean ± SEM, with p < 0.05 considered to be statistically
significant.
RESULTS
KCa3.1 Is Up-Regulated in Reactive
Astrocytes of TgAPP/PS1 Mice and AD
Patients
We recently showed that KCa3.1 expression is increased in both
reactive astrocytes and neurons in the brains of SAMP8 mice, a
model that is generally used to investigate the mechanisms of age-
related memory deficits (Yi et al., 2016b). In the present study,
expression of KCa3.1 was detected in the brains of TgAPP/PS1
mice at 9 months of age and in AD patients. Age-matched
WT littermates and healthy humans were used as controls.
In WT mice (Figure 1A) and healthy humans (Figure 2A),
there was little co-localization between KCa3.1 and GFAP+
astrocytes. In 9 month old TgAPP/PS1 mice (Figure 1A) and
AD patients (Figure 2A), KCa3.1 was detected in GFAP+
hypertrophic astrogliosis. Kaushal et al. (2007) reported that
KCa3.1 is expressed in rat neurons in vitro. In the present study,
expression of KCa3.1 was shown to be higher in NeuN+ neurons
of TgAPP/PS1 mice (Figure 1B) and AD patients (Figure 2B) than
in WT mice and control humans, where expression levels are
low. Although there is convincing evidence for the expression
of KCa3.1 on microglia in vitro, data supporting expression of
KCa3.1 on microglia in vivo are scarce (Kaushal et al., 2007). In
this study, rare co-localization of KCa3.1 and Iba1+ microglia
was detected in brain slices of both WT and TgAPP/PS1 mice
(Figure 1C) and control humans and AD patients (Figure 2C).
KCa3.1 was expressed at low levels, mainly in neurons, in WT
mice and control humans. In TgAPP/PS1 mice and AD patients,
KCa3.1 expression was up-regulated in neurons and was also
observed in astrocytes.
Blockade of KCa3.1 Rescues Memory
Deficits and Spontaneous Motor Activity
in TgAPP/PS1 Mice
In a previous study, we showed that inhibition of KCa3.1
channels attenuated memory deficits in SAMP8 mice (Yi
et al., 2016b). In the present study, TRAM-34 (120 mg/kg,
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FIGURE 4 | Blockade of KCa3.1 attenuated gliosis and neuronal loss in TgAPP/PS1 mice. (A) Representative images of GFAP-immunoreactive astrocytes
from hippocampal regions of WT and Tg mice, with and without TRAM-34 (120 mg/kg/d). (B) Quantification of reactive astrocyte number/0.01 mm2 in hippocampus
(n = 6–8). (C) Iba1 immunoreactivity of activated microglia from hippocampal regions of WT and Tg mice, with and without TRAM-34 (120 mg/kg/d).
(D) Quantification of activated microglial number/0.01 mm2 in hippocampus (n = 6–8). NeuN immunoreactivity of neurons in (E) cortex and (G) hippocampal regions
of WT and Tg mice, with and without TRAM-34 (120 mg/kg/d). Quantification of neuron number/0.01 mm2 in (F) cortex and (H) hippocampus (n = 6–8). Data
represent mean ± SEM. #p < 0.05, ##p < 0.01 compared with WT mice. ∗p < 0.05, versus Tg mice (n = 6–8). (I) Western blot analysis using antibodies to
astrocyte marker GFAP, dendritic protein MAP2, post-synaptic protein PSD95, and pre-synaptic protein synaptophysin. (J) Results are presented as mean ± SEM
(n = 4). #p < 0.05, ##p < 0.01 compared with WT mice. ∗p < 0.05, ∗∗p < 0.01 compared with Tg mice. Tg, TgAPP/PS1. Scale bar: 25 µm.
intraperitoneally) was used to test whether pharmacological
blockade of KCa3.1 would attenuate loss of memory and
spontaneous motor activity in TgAPP/PS1 mice, and the dosage
of TRAM-34 was used as previously described (Bouhy et al.,
2011; Chen et al., 2016; Yi et al., 2016b). Nine months
old TgAPP/PS1 mice were treated once daily with TRAM-
34 (120 mg/kg, intraperitoneally) or vehicle for 4 weeks
and the Morris water maze test and open field test were
then used to assess memory and motor activity, respectively.
In the hidden platform arm of the Morris water maze
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FIGURE 5 | Blockade of KCa3.1 attenuated β-amyloid burden in the brains of TgAPP/PS1 mice. Mouse anti-6E10 monoclonal antibody was used to detect
senile plaques in (A) brain cortex and (C) hippocampus of WT, TgAPP/PS1, and TgAPP/PS1 + TRAM-34 (120 mg/kg) groups (n = 10 per group). Quantification of
senile plaque numbers in (B) cortex and (D) hippocampus. Data represent mean ± SEM. ##p < 0.01, versus WT mice. ∗∗p < 0.01, versus vehicle-treated TgAPP/PS1
mice. Scale bar: 50 µm.
FIGURE 6 | Blockade of KCa3.1 attenuated expression and release of
inflammatory mediators in the brains of TgAPP/PS1 mice. Western blots
showing protein expression of (A,B) iNOS and (C,D) COX-2 proteins in the
brains of WT and TgAPP/PS1 mice, with or without treatment with TRAM-34
(n = 4), at the age of 9 months. Measurement of (E) TNF-α and (F) IL-1β
released by ELISA in homogenated cortex of WT and TgAPP/PS1 mice, with or
without treatment with TRAM-34 (n = 4) at the age of 9 months. Data
represent mean ± SEM. ##p < 0.01 compared with WT mice. ∗p < 0.05,
∗∗p < 0.01 compared with TgAPP/PS1 mice.
test, the TgAPP/PS1 + vehicle group showed memory deficits
compared with WT mice. The TgAPP/PS1 + TRAM-34 group
showed significantly improved spatial learning and memory
compared with the TgAPP/PS1 + vehicle group (p < 0.05,
Figure 3A). In the spatial probe trial without an escape
platform, the TgAPP/PS1 + TRAM-34 group spent more time
and swam for greater distances in the target quadrant than the
TgAPP/PS1 + vehicle group (p < 0.05, Figures 3B,C).
In the open field test, the TgAPP/PS1 + vehicle group had a
decreased ratio distance (p < 0.01, Figure 3D) and ratio time
(p < 0.01, Figure 3E) in the center compared to WT mice. In
contrast, the TgAPP/PS1 + TRAM-34 group had a significantly
greater ratio distance (p < 0.05, Figure 3D) and more ratio time
(p < 0.05, Figure 3E) in the center than the TgAPP/PS1 + vehicle
group.
Blockade of KCa3.1 Attenuates Gliosis
and Loss of Neurons in TgAPP/PS1 Mice
Reactive astrogliosis is a common pathological feature of chronic
neurological diseases associated with aging, such as AD (Khakh
and Sofroniew, 2015). We have previously shown that inhibition
of KCa3.1 reduces the reactive astrogliosis response (Yu et al.,
2014). In the present study, both GFAP+-reactive astrocytes
and Iba1+-activated microglia were significantly increased in
the TgAPP/PS1 + vehicle group compared with WT mice. The
TgAPP/PS1 + TRAM-34 group, however, showed a significantly
suppressed astrogliosis response (p < 0.05, Figures 4A,B)
and reduced numbers of activated microglia (p < 0.05,
Figures 4C,D) compared with the TgAPP/PS1 + vehicle group.
The TgAPP/PS1 + TRAM-34 group also showed reduced neuronal
loss in the cortex (p< 0.05, Figures 4E,F) and CA1 hippocampus
(p < 0.05, Figures 4G,H). Significantly more NeuN+ neurons
were present in the TgAPP/PS1 + TRAM-34 group than in the
TgAPP/PS1 + vehicle group.
Because dendritic and synaptic damage, as well as neuronal
loss, likely play important roles in the process of AD, we
questioned whether astrogliosis damages dendrites and synapses.
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FIGURE 7 | KCa3.1 is involved in Aβ oligomer-induced astrogliosis. (A) Western blot showing protein expression of astrocytic GFAP and KCa3.1 after
treatment with Aβ (5 µM) for 1, 2, 3, or 5 days (n = 3). (B) Data are presented as mean ± SEM. ∗∗p < 0.01 compared with control. (C) Western blot showing
expression of GFAP protein after stimulation with Aβ (5 µM), with or without TRAM-34 (1 µM) for 3 days (n = 3). (D) Data represent mean ± SEM. ∗∗p < 0.01
compared with Aβ-treatment group; ##p < 0.01 compared with control. Con, control.
Western blotting demonstrated that treatment with TRAM-
34 (120 mg/kg) significantly reduced levels of astrogliosis and
increased expression of dendritic marker MAP2 and excitatory
synapses marker PSD95, but not the pre-synaptic marker
synaptophysin, in TgAPP/PS1 mice (Figures 4I,J).
Blockade of KCa3.1 Decreases Amyloid
Deposition and Inflammatory Cytokine
Production in TgAPP/PS1 Mice
To investigate whether inhibition of KCa3.1 channels can
attenuate amyloid accumulation, cerebral senile plaques in the
different groups of mice were visualized using 6E10 staining.
Senile plaque formation in both cortex and hippocampus
was significantly increased in the TgAPP/PS1 + vehicle group
compared with WT mice (p < 0.01, Figures 5A–D). After
treatment with TRAM-34 (120 mg/kg, i.p.) for 4 weeks, TgAPP/PS1
mice showed decreased senile plaque formation. Quantification
showed that senile plaque formation was decreased in the cortex
(p < 0.01; Figure 5B) but not in the hippocampus (p > 0.05;
Figure 5D) in the TgAPP/PS1 + TRAM-34 group compared
with the TgAPP/PS1 + vehicle group. Given the contribution of
gliosis to Aβ production, the decrease in senile plaque formation
seen in the cortex of TgAPP/PS1 + TRAM-34 group is likely
attributable to a reduction in numbers of reactive astrocytes
and active microglia, brought about by inhibition of KCa3.1
channels.
Neuronal death in AD is largely caused by the release
of pro-inflammatory mediators during gliosis (Scuderi et al.,
2014). Blockade of KCa3.1 inhibited the up-regulation of iNOS
(Figures 6A,B) and COX-2 (Figures 6C,D), compared with
vehicle-treated TgAPP/PS1 mice. Levels of IL-1β and TNF-α in
brain homogenates from the different groups were measured by
ELISA experiments (Figures 6E,F). Levels of both IL-1β and
TNF-α released were attenuated in the TgAPP/PS1 + TRAM-34
group compared with the TgAPP/PS1 + vehicle group. These data
demonstrate that KCa3.1 is involved in activation of glial cells in
a mouse model of AD.
Blockade of KCa3.1 Attenuated
Aβ-Induced Reactive Astrogliosis
through JNK Signaling Pathways
We first tested whether Aβ-induced astrogliosis was associated
with KCa3.1 expression in vitro. Primary astrocytes cultured in
the presence of Aβ (5 µM) showed up-regulated GFAP and
KCa3.1 (Figures 7A,B). The up-regulation of GFAP was blocked
by pre-treatment with TRAM-34 (1 µM; Figures 7C,D). The
concentration of TRAM-34 (1 µM) was used as previously
described (Bouhy et al., 2011; Yu et al., 2014).
Reactive astrocytes release a variety of cytokines and pro-
inflammatory mediators, which activate intracellular MAPK
signaling pathways (Matos et al., 2008). We examined whether
the involvement of KCa3.1 in Aβ-induced astrogliosis is mediated
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FIGURE 8 | KCa3.1 is involved in Aβ-induced generation of activated astrocyte phenotype. (A) Representative images of total JNK/ERK/P38 and
p-JNK/p-ERK/p-P38, in control astrocytes and Aβ-stimulated astrocytes (30 min), with or without TRAM-34 (1 µM) treatment. (B–D) Mean values of
p-JNK/p-ERK/p-P38 activity relative to total JNK/ERK/P38 (n = 3–6). Results are presented as mean ± SEM. #p < 0.05, ##p < 0.01 versus control, ∗∗p < 0.01
versus Aβ-stimulated alone. (E,F) Western blots showing expression of GFAP protein in astrocytes after 3 days Aβ stimulation in the presence of SP600125 (10 µM;
n = 3). Data are presented as mean ± SEM. ##p < 0.01 versus control, ∗p < 0.05 versus Aβ. (G) CM-H2DCFDA (30 µM) was used to measure the level of reactive
oxygen species (ROS) generation induced by Aβ in astrocytes. (H) ROS generation was reduced by TRAM-34 (1 µM) in astrocytes treated with Aβ (n = 5). Data
represent mean ± SEM. β-actin was used as an internal control. ##p < 0.01, ∗∗∗p < 0.001, ∗p < 0.05 compared with control; ∗∗p < 0.01 compared with Aβ-treated
cells.
by the ERK, JNK, and p38 signaling pathways (Figures 8A–D).
Astrocytes exposed to Aβ (5 µM) for 30 min showed up-
regulated phosphorylation of JNK (Figures 8A,B) and ERK
(Figures 8A,C) but only phosphorylation of JNK was inhibited by
TRAM-34 (1 µM; Figure 8B). Treatment with the JNK inhibitor
SP600125 (10 µM) for 3 days attenuated Aβ-induced GFAP
protein expression in astrocytes (Figures 8E,F).
The molecular probe CM-H2DCFDA, which detects
intracellular ROS levels, was used to determine whether KCa3.1
contributed to ROS production via Aβ-induced astrogliosis.
After treatment with Aβ oligomer (5 µM) for 30 min, a rapid
transient increase in the DCF signal was detected (Figure 8G).
ROS production at 30 min was inhibited by TRAM-34 (p < 0.01,
Figure 8H). These data demonstrate that KCa3.1 is involved in
reactive astrocytosis and oxidative stress via the JNK signaling
cascades.
Blockade of KCa3.1 Attenuated Indirect
Aβ-Induced Neurotoxicity Mediated by
Astrocytes
It has been reported that astrocytes accelerate Aβ-induced
neurotoxicity (Garwood et al., 2011). To determine whether
or not KCa3.1 is involved in astrocyte-accelerated Aβ-induced
neurotoxicity, neurons, astrocytes and mixed cultures (neurons
with astrocytes) were treated with 5 µM Aβ oligomers and
then cell viability was measured in the different groups at 48 or
72 h (Figures 9A–E). Treatment with 1 µM TRAM-34 alone
did not significantly change the viability of any of these cell
cultures. Pre-treatment of mixed cultures, but not neuronal
cultures, with TRAM-34 before treatment with Aβ increased
cell viability at both 48 and 72 h (Figures 9A,C), suggesting
that TRAM-34 might reduce Aβ-induced neurotoxicity by
suppressing astrogliosis. A significant decrease in cell viability
was observed only after 72 h in Aβ-treated neuronal cultures
(Figures 9B,D). Aβ oligomers did not cause decreased viability
from astrocytes at 72 h (Figure 9E), indicating that the phenotype
switch of astrogliosis significantly accelerates Aβ-induced
neurotoxicity.
We next asked whether blockade of KCa3.1 might attenuate
neurotoxicity induced by inflammatory mediators during
astrogliosis. Pre-treatment with TRAM-34 (1 µM) was found
to rescue neuronal viability in cultures treated with astrocytes
CM (Figure 10A). As a negative control, neuronal viability was
not significantly affected by cell-free astrocyte CM that had been
incubated for 48 h with Aβ (5 µM; Figure 10B).
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FIGURE 9 | KCa3.1 is involved in astrocyte-accelerated Aβ-induced neurotoxicity. Bar charts showing cell viability of (A,C) mouse primary mixed cultures
and (B,D) neuronal cultures treated with Aβ (5 µM) for (A,B) 48 or (C,D) 72 h, with or without pre-treatment with TRAM-34 (1 µM). (E) Cell viability of mouse primary
astrocytes treated for 72 h with Aβ (5 µM), with and without pre-treatment with TRAM-34 (1 µM). Data represent mean ± SEM of cell viability relative to control
(n = 4 cultures). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
FIGURE 10 | Aβ-induced indirect, astrogliosis-mediated neurotoxicity. Bar charts showed cell viability of neurons exposed to (A) CM from astrocytes treated
with Aβ (5 µM), with or without TRAM-34 (1 µM) and (B) cell-free astrocytes culture medium treated with Aβ (5 µM) for 48 h, with or without TRAM-34 (1 µM). Data
represent mean ± SEM of cell viability relative to control (n = 4 cultures). ∗p < 0.05, ∗∗∗p < 0.001. CM, conditioned medium.
Because damage to dendrites and synapses occurs before
neuronal loss during the development of AD (Szegedi et al.,
2006), we asked whether Aβ-induced astrogliosis-mediated by
KCa3.1 could accelerate damage to dendrites and synapses. More
signs of dendritic and synaptic damage were observed in neurons
treated with Aβ-treated astrocytes CM than in those treated with
control CM, as demonstrated by immunofluorescent staining
for the dendritic marker MAP2 (Figure 11A). Incubation with
Aβ-CM decreased total neurite length (Figure 11B) and number
of branch points (Figure 11C). Pre-incubation with TRAM-34
(1 and 10 µM) markedly reversed the effect of Aβ-CM by
increasing total neurite length and number of branch points
(Figures 11A–C). The concentrations of TRAM-34 (1 and
10 µM) were used as previously described (Lallet-Daher et al.,
2009; Yu et al., 2014). Western blots showed that blockade
of KCa3.1 attenuated Aβ-CM-induced decreases in NeuN,
MAP2, and PSD95, but not decreases in the pre-synaptic
marker, synaptophysin (Figures 11D,E). Taken together, these
results show that KCa3.1 is involved in Aβ-mediated damage
to dendrites and synapses by an indirect, astrogliosis-mediated
mechanism.
DISCUSSION
The data presented herein demonstrate that blockade of KCa3.1
attenuates neuropathology by regulating neuroinflammation in
a mouse model of AD and, moreover, that prevention of
astrogliosis might be a promising strategy for the treatment of
AD. Using TgAPP/PS1 mice as a model of AD, we have shown
that pharmacological blockade of KCa3.1 significantly reduced
astrogliosis, neuronal loss, and memory deficits. KCa3.1 blockade
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FIGURE 11 | Blockade of KCa3.1 attenuated Aβ-induced, indirect, astrocyte-mediated damage to dendrites and synapses. Levels of dendritic and
synaptic markers were compared between hippocampal neurons treated with solvent only (control treatment), 5 µM Aβ, Aβ-CM, or CM from astrocyte cultures in
which Aβ-induced activation was inhibited for 24 h by TRAM-34 (TRAM-34 + Aβ-CM). A Cellomics KineticScan HCS Reader was used to image the primary cerebral
neurons. (A) For better visualization of individual dendrites, dendrites of the sparsely plated neurons were immunostained with MAP2 (red), and nuclei were stained
with DAPI (blue). Extended Neurite Outgrowth bioapplication software was used to analyze (B) neurite length and (C) branch point counts. Data represent
mean ± SEM (n = 3). ∗∗p < 0.01, ∗∗∗p < 0.001 compared with Aβ-CM. ##p < 0.01 compared with control. Aβ-CM treatment significantly reduced neurite length
and branch point counts. This reduction was prevented by inhibition of astrocyte activation by TRAM-34 (1 and 10 µM; n = 3). (D) Western blot analysis with the
following primary antibodies: neuronal marker NeuN, dendritic marker MAP2, post-synaptic proteins PSD95, and pre-synaptic protein synaptophysin. (E) Results are
presented as mean ± SEM (n = 3). #p < 0.05 compared with con-CM. ∗p < 0.05 compared with Aβ-CM. CM, conditioned medium.
inhibited astrocyte activation and reduced levels of IL-1β, TNF-
α, iNOS, and COX-2 in the brain. In vitro experiments with
primary murine neuronal, astrocytic and mixed cortical cultures
exposed to Aβ confirmed that blockade of KCa3.1 improved
neuronal survival by reducing astrocyte activation and ROS
production.
Deposits of Aβ could induce oxidative stress, glial activation,
and local cell loss. In the progression of AD, astrocytes undergo
a switch to a reactive phenotype, characterized by profound
functional and morphological alterations (O’Callaghan et al.,
2014). Up-regulation of the astrogliosis marker GFAP is a well-
characterized example of these phenotypical changes and, in
our cellular model, TRAM-34 was found to negatively modulate
expression of both GFAP and KCa3.1.
There is a large body of data that implicates MAPK signaling
pathways, especially JNK pathways, in oxidative stress (Matos
et al., 2008). In the present study, blockade of KCa3.1 attenuated
phosphorylation of JNK, which is activated by Aβ stimulation.
Astrogliosis has been shown to contribute to inflammatory
processes in AD through the release of ROS, pro-inflammatory
factors, and cytokines (Heneka et al., 2001; Verkhratsky et al.,
2010). For example, IL-1β, TNF-α, ROS, and NO have been
found to regulate pro- and anti-inflammatory genes, including
NOS-2 and COX-2 (Tuppo and Arias, 2005; Wyss-Coray, 2006).
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We found that blockade of KCa3.1 attenuated Aβ-induced
indirect neurotoxicity and decreased Aβ-mediated damage to
dendrites and synapses by an indirect, astrogliosis-mediated
mechanism. In the AD mouse model, levels of pro-inflammatory
factors and cytokines were significantly up-regulated and these
increases were inhibited by TRAM-34.
The tripartite synapses in the CNS are formed by pre- and
post-synaptic neuronal compartments and astroglial perisynaptic
processes (Verkhratsky et al., 2010). A phenotype switch of
astrocytes may lead to abnormal release of gliotransmitters, such
as glutamate and GABA, which could lead to synaptic loss,
excitotoxicity, and neurodegeneration in AD (Agulhon et al.,
2012; Jo et al., 2014). Numerous clinical studies have confirmed
a correlation between the degree of dementia and the extent
of synaptic loss. In our studies, blockade of KCa3.1 rescued
memory deficits, and synapse/neuron loss in TgAPP/PS1 mice.
After treatment with TRAM-34, quantification showed that senile
plaque formation was decreased in the cortex (Figure 5B) but
not in the hippocampus (Figure 5D). We propose that the
different efficacy with respect to different brain areas is that the
hippocampus was the greatest amyloid burden region in mice
model of AD (Reilly et al., 2003), and the processes of astrogliosis
mostly observed surrounding amyloid plaques also were able
to accumulate large amounts of senile plaque (Rodriguez
et al., 2009). Reducing astrogliosis is a promising strategy for
controlling harmful CNS inflammation in neurodegenerative
disorders (Khakh and Sofroniew, 2015; Sofroniew, 2015).
In the present in vivo study, we found that KCa3.1
was up-regulated in reactive astrocytes of TgAPP/PS1 mice
and AD patients compared with WT mice and control
humans. It has also been reported that KCa3.1 is involved
in several aspects of microglial activation in vitro (Kaushal
et al., 2007; Maezawa et al., 2011; Ferreira and Schlichter,
2013). Maezawa et al. (2011) reported that KCa3.1 activity
is required for Aβ-induced microglial neurotoxicity in vitro.
In our study, KCa3.1 channels were rarely co-localized
with microglia, although blockade of KCa3.1 reduced both
astrogliosis and microglial activation in TgAPP/PS1 mice.
Based on these results, we propose that the expression
of KCa3.1 is under the immunohistochemically detectable
levels in microglia of both mice and human. Co-cultures
of astrocytes and neurons were established to determine
whether or not KCa3.1 is involved in astrocyte-accelerated
Aβ-induced neurotoxicity. Our data suggest that TRAM-
34 might reduce Aβ-induced neurotoxicity by suppressing
astrogliosis.
The mechanism of the Aβ-induced phenotypic switch of
astrocytes and its potential role in the progression of AD
provide excellent opportunities for novel therapies such as
TRAM-34, a small molecule blocker of KCa3.1. We have
provided evidence that KCa3.1 regulates Aβ-induced astrogliosis
and neurotoxicity. The anti-inflammatory and neuroprotective
properties of KCa3.1 blockers have been demonstrated in many
animal models, including traumatic brain injury, retinal ganglion
cell degeneration, and multiple sclerosis (Mauler et al., 2004;
Reich et al., 2005; Kaushal et al., 2007; Yi et al., 2016b). Our
data show that KCa3.1 is also a promising target for reducing
inflammatory damage in AD.
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